Yellow

VITRAKVI® is an oral medicine that is not a chemotherapy

  • VITRAKVI is the first medicine specifically designed to block TRK proteins
  • VITRAKVI is thought to work by blocking these proteins and stopping cancer cells from growing, but the exact way VITRAKVI works is unknown
  • VITRAKVI can work in a variety of tumor types as long as the tumor is caused by an NTRK gene fusion
card

Are you and your doctor considering treatment with VITRAKVI?

Before you can take VITRAKVI, your healthcare provider will perform a test to make sure that VITRAKVI is right for you.

women
Learn More About TRK Fusion Cancer and Testing
card

Have you been prescribed VITRAKVI?

VITRAKVI was exclusively designed to treat TRK fusion cancer.

father daughter
See How VITRAKVI Has
Helped Patients
voices

VITRAKVI Voices: Your story can inspire others

What is VITRAKVI?

If you are a patient currently taking VITRAKVI or are a caregiver, we would love to hear about your personal experience.

VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:

  • are caused by certain abnormal NTRK genes and

  • have spread or if surgery to remove their cancer is likely to cause severe complications, and

  • there is no acceptable treatment option or the cancer grew or spread on other treatment.

Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.

It is not known if VITRAKVI is safe and effective in children younger than 28 days of age.

VITRAKVI was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long that response lasted. There are ongoing studies to confirm the benefit of VITRAKVI for this use.

Share Your Story

What is VITRAKVI?

If you are a patient currently taking VITRAKVI or are a caregiver, we would love to hear about your personal experience.

  • are caused by certain abnormal NTRK genes and

  • have spread or if surgery to remove their cancer is likely to cause severe complications, and

  • there is no acceptable treatment option or the cancer grew or spread on other treatment.

Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.

It is not known if VITRAKVI is safe and effective in children younger than 28 days of age.

VITRAKVI was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long that response lasted. There are ongoing studies to confirm the benefit of VITRAKVI for this use.

voices img
Let’s Keep in Touch

Let’s Keep in Touch

If you would like more information and the latest news about VITRAKVI, register now to receive future updates.

Register for Updates